2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100635S
    Diacetolol-d7 1346604-19-0 98%
    Diacetolol-d7 is a deuterium labeled Diacetolol. Diacetolol is the major metabolite of Acebutolol. Diacetolol is a β-adrenoceptor blocking and anti-arrhythmic agent.
    Diacetolol-d7
  • HY-100652A
    O-Desmethyl apixaban sulfate sodium 98%
    O-Desmethyl apixaban sulfate sodium is a major circulating metabolite of Apixaban in humans. O-Desmethyl apixaban sulfate sodium inhibits factor X (FXa) with a Ki of 58 μM.
    O-Desmethyl apixaban sulfate sodium
  • HY-100655R
    O-Desmethyl apixaban (Standard) 503612-76-8
    O-Desmethyl apixaban (Standard) is the analytical standard of O-Desmethyl apixaban. This product is intended for research and analytical applications. O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01). Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
    O-Desmethyl apixaban (Standard)
  • HY-100750R
    Norverapamil hydrochloride (Standard) 67812-42-4
    Norverapamil (hydrochloride) (Standard) is the analytical standard of Norverapamil (hydrochloride). This product is intended for research and analytical applications. Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].
    Norverapamil hydrochloride (Standard)
  • HY-100957R
    Dilazep dihydrochloride (Standard) 20153-98-4
    Dilazep (dihydrochloride) (Standard) is the analytical standard of Dilazep (dihydrochloride). This product is intended for research and analytical applications. Dilazep dihydrochloride is an inhibitor of adenosine uptake. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. Dilazep dihydrochloride also inhibits the ischemic damage, platelet aggregation, and membrane transport of nucleosides.
    Dilazep dihydrochloride (Standard)
  • HY-100986B
    L-NIO 36889-13-1 98%
    L-NIO is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO induces a consistentfocal ischemic infarctin rats.
    L-NIO
  • HY-10119AR
    Vorapaxar sulfate (Standard) 705260-08-8
    Vorapaxar (sulfate) (Standard) is the analytical standard of Vorapaxar (sulfate). This product is intended for research and analytical applications. Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.
    Vorapaxar sulfate (Standard)
  • HY-101200R
    Linsidomine hydrochloride (Standard) 16142-27-1
    Linsidomine (hydrochloride) (Standard) is the analytical standard of Linsidomine (hydrochloride). This product is intended for research and analytical applications. Linsidomine hydrochloride (SIN-1 chloride) is a spontaneous ROS/RNS generator and peroxynitrite donor. Linsidomine hydrochloride is a vasodilator and platelet aggregation inhibitor. Linsidomine hydrochloride induces oxidative stress-induced chondrocyte apoptosis and necrosis. Linsidomine hydrochloride inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of Linsidomine hydrochloride shows protective effects on Zn2+ treated nerve cells.
    Linsidomine hydrochloride (Standard)
  • HY-101205A
    ICI-199441 116508-24-8 98%
    ICI-199441 is a potent and selective κ-opioid receptor agonist with analgesic effects. ICI 199441 can improve heart resistance to ischemia/reperfusion.
    ICI-199441
  • HY-101390B
    Niguldipine free base 102993-22-6 98%
    Niguldipine free base is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine free base can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine free base exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine free base also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine free base on myocardial metabolism is not significant.
    Niguldipine free base
  • HY-101607A
    KT-362 free acid 93392-97-3 98%
    KT-362 free acid is an intracellular calcium antagonist with antiarrhythmic and vasodilatory effects. KT-362 free acid shows an antagonistic effect against norepinephrine (NE) induced vasoconstriction response, achieved by reducing inositol phospholipid hydrolysis, thereby reducing intracellular calcium mobilization. KT-362 free acid can be used to study the contraction and relaxation mechanisms of vascular smooth muscle, especially in exploring the role of intracellular calcium mobilization and inositol phospholipid hydrolysis in vascular contraction.
    KT-362 free acid
  • HY-101617A
    Droxicainide hydrochloride 149572-05-4 98%
    Droxicainide hydrochloride is an antiarrhythmic agent.
    Droxicainide hydrochloride
  • HY-10163S2
    Dabigatran-13C6 1210608-88-0 98%
    Dabigatran-13C6 is the 13C labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-13C6
  • HY-10163S3
    Dabigatran-13C,d3 98%
    Dabigatran-13C,d3 is the 13C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-13C,d3
  • HY-10163S5
    Dabigatran-d7 2512224-24-5 98%
    Dabigatran-d7 (BIBR 953-d7; BIBR 953ZW-d7) is the deuterium labeled Dabigatran (HY-10163). Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-d7
  • HY-101682B
    (R)-SCH 42495 156792-25-5 98%
    (R)-SCH 42495 is the less active enantiomer of SCH 42495. SCH 42495 is an orally active neutral metalloendopeptidase (NEP) inhibitor with antihypertensive effect. SCH 42495 is the orally active ethylester proagent of SCH 42354.
    (R)-SCH 42495
  • HY-101685A
    Iganidipine di(hydrochloride) 117241-46-0 98%
    Iganidipine dihydrochloride is a Ca2+ antagonist.
    Iganidipine di(hydrochloride)
  • HY-101700A
    LCB 2853 sodium 141335-11-7 98%
    LCB 2853 (sodium) is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist. LCB 2853 (sodium) exhibits anti-aggregant and anti-vasospastic effects. LCB 2853 (sodium) can be used for the research of cardiovascular disease, such as hypertension.
    LCB 2853 sodium
  • HY-101704A
    Y1 receptor antagonist 1 formic 99.84%
    Y1 receptor antagonist 1 (H 409-22 isomer) formic (Example 4) is a neuropeptide Y1 receptor antagonist. Y1 receptor antagonist 1 can be used for the study of cardiovascular diseases, such as vasoconstriction.
    Y1 receptor antagonist 1 formic
  • HY-101723R
    Modecainide (Standard) 81329-71-7
    Modecainide (Standard) is the analytical standard of Modecainide. This product is intended for research and analytical applications. Modecainide is a major metabolite of Encainide, which is an antiarrhythmic agent.
    Modecainide (Standard)
Cat. No. Product Name / Synonyms Application Reactivity